10-Q: OmniAb Reports Q2 Loss Amid Revenue Declines

OmniAb, Inc. reported a significant net loss for Q2 2025, driven by substantial declines in license, milestone, service, and royalty revenues, despite reduced operating expenses.

Summary

• Net loss for the three months ended June 30, 2025, was $15.875 million, an increase from $13.631 million in the same period of 2024.
• Total revenue for the three months ended June 30, 2025, decreased by 49% to $3.897 million from $7.614 million in the prior year period.
• For the six months ended June 30, 2025, total revenue was $8.051 million, down 29% from $11.415 million in the prior year period.
• Cash and cash equivalents decreased to $18.281 million as of June 30, 2025, from $27.598 million at December 31, 2024.
• Short-term investments also declined to $23.334 million from $31.836 million over the same period.
• Operating activities used $21.018 million in cash during the six months ended June 30, 2025, an improvement from $29.214 million used in the prior year period.
• The company had 100 active partners and 381 active programs as of June 30, 2025, up from 91 partners and 363 programs at December 31, 2024.
• Active clinical programs and approved products remained flat at 32 and 3, respectively, as of June 30, 2025.
• A gain of $3.0 million was recognized from the sale of a small molecule Kv7.2 program to Angelini Pharma S.p.A. in May 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in all revenue streams and an increased net loss. While operating cash burn improved and expenses were reduced, the core business revenue performance is weak. The declining cash reserves and out-of-the-money warrants suggest potential future capital needs, despite management's 12-month liquidity assurance. The new healthcare reform risk adds further uncertainty.

Positives

• Cash used in operating activities improved, decreasing to $21.018 million for the six months ended June 30, 2025, from $29.214 million in the prior year period.
• Total costs and operating expenses decreased by 16% for the three months and 14% for the six months ended June 30, 2025, primarily due to lower research and development and general and administrative expenses.
• Research and development expenses decreased by 22% for the three months and 18% for the six months ended June 30, 2025, due to lower personnel expenses (including share-based compensation and headcount) and reduced external expenses.
• General and administrative expenses declined by 4% for both the three and six months ended June 30, 2025, due to lower legal fees and share-based compensation.
• The company recorded a $3.0 million gain from the sale of an ion channel asset to Angelini Pharma S.p.A. in May 2025.
• Active partners increased to 100 from 91, and active programs increased to 381 from 363, indicating continued engagement and new opportunities for the technology platform.

Negatives

• Net loss increased to $15.875 million for the three months ended June 30, 2025, from $13.631 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $34.075 million from $32.592 million in the prior year period.
• Total revenue decreased significantly by 49% for the three months and 29% for the six months ended June 30, 2025, compared to the prior year periods.
• License and milestone revenue declined by 60% for the three months and 15% for the six months ended June 30, 2025, primarily due to a decline in milestone revenue.
• Service revenue decreased by 54% for the three months and 45% for the six months ended June 30, 2025, mainly due to the discontinuation of a small molecule ion channel program and related revenue acceleration in the prior year.
• Royalty revenue declined by 65% for the three months and 53% for the six months ended June 30, 2025, primarily due to lower net sales from partners' product sales in China.
• Cash, cash equivalents, and short-term investments decreased from $59.434 million at December 31, 2024, to $41.615 million at June 30, 2025.
• The company's warrants are currently out of the money, meaning the trading price of common stock is below the $11.50 exercise price, and no cash proceeds are expected from their exercise in the near term.

Risks

• The company's ability to achieve revenue growth is dependent on partners successfully developing and commercializing therapies based on its antibody discovery platform.
• There is significant uncertainty in the timing and likelihood of reaching marketing authorization in drug discovery and development, impacting when royalty payments will become a material portion of revenue.
• The company does not control the progression, clinical development, regulatory strategy, or eventual commercialization of programs discovered using its platform, making it dependent on partners' efforts and decisions.
• The company relies on partners to provide timely and accurate information regarding program status and milestone achievements, which impacts the accuracy of key business metrics.
• Recent government healthcare reform, specifically the 'One Big Beautiful Bill Act' enacted in July 2025, imposes significant reductions in Medicaid program funding, which could decrease enrollment and covered services, adversely affecting partners' product sales and commercialization efforts.
• Changes in reimbursement and pricing actions in various states have negatively affected, and may continue to negatively affect, pharmaceutical products, potentially limiting prices or complicating drug distribution.

Future Outlook

The company expects to continue incurring losses as it invests in research and development, markets its technologies, and expands operations. It believes existing cash, cash equivalents, and short-term investments are sufficient to support operations for at least the next 12 months. Future capital requirements depend on revenue growth, expansion costs, R&D progress, competitive developments, and intellectual property costs. The long-term value of the business is expected to be driven by royalties from partner programs, while milestones are anticipated to drive shorter-term revenue, though timing and likelihood of marketing authorization are uncertain.

Management Comments

• We believe our existing cash, cash equivalents and short-term investments are sufficient to support operations through at least the next 12 months from the date of issuance of these financial statements.
• We believe the OmniAb animals comprise the most diverse host systems available in the industry.
• We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research and milestone payments.
• We believe our revenue will be materially driven by milestones in the shorter term, and by royalties in the longer term, from our partnered programs.
• We do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform, and as a result, we are dependent on our partners efforts and decisions with respect to such programs.

Industry Context

OmniAb operates in the biotechnology sector, specializing in antibody discovery and therapeutic development. The company's business model relies heavily on licensing its technology platform and earning revenue through upfront fees, research services, milestones, and royalties from its partners. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. The company's focus on 'Biological Intelligence' and 'in silico, artificial intelligence and machine learning tools' aligns with broader industry trends towards advanced computational methods in drug discovery. The mention of the 'One Big Beautiful Bill Act' highlights the increasing impact of government healthcare policy on the pharmaceutical industry, potentially affecting the commercial success of partner products.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct industry standard comparison. The company's performance is presented in isolation relative to its own prior periods.

Legal Proceedings

• The company is involved in various legal proceedings arising in its ordinary course of business, but management does not expect resolution of any pending claims to have a material adverse impact on the condensed consolidated financial statements, cash flows, or financial position.

Stakeholder Impact

• Shareholders: Face increased net losses and declining revenue, potentially impacting share price and future profitability. Dilution risk exists due to the ATM offering and potential future capital raises.
• Employees: Personnel expenses were lower due to reduced headcount, indicating potential job impacts.
• Partners: The company's success is tied to its partners' ability to develop and commercialize therapies, and new healthcare legislation could impact partners' sales and, consequently, OmniAb's royalty revenue.
• Creditors: The company's liquidity position, while stated as sufficient for 12 months, shows a decline in cash and investments, which could be a concern if revenue trends do not reverse.

Next Steps

• Continue to invest in research and development activities to improve the technology platform.
• Market and sell technologies to existing and new partners.
• Add operational, financial, and management information systems and personnel to support operations.
• Monitor and adapt to the impact of government healthcare reform and other legislative measures on the pharmaceutical industry and partner product sales.

Key Dates

Recommendation

The company reported substantial declines across all revenue categories and an increased net loss, indicating a deteriorating financial performance. While operating expenses were reduced, the core business is struggling to generate revenue. The significant decrease in cash and short-term investments, coupled with out-of-the-money warrants, suggests potential future capital needs and dilution risk. New legislative risks further cloud the outlook for partner product sales. Given the negative financial trends and uncertainties, a seasoned investor would likely consider selling or avoiding this stock until there are clear signs of revenue stabilization and a path to profitability.

Keywords

Biotechnology, Antibody discovery, Therapeutics, SEC filing, Financial results, Q2 2025, Revenue decline, Net loss, Cash flow, Research and development, Licensing, Milestones, Royalties, Healthcare reform, Risk factors, OABI